LivaNova (LIVN) Downgraded to “Hold” at ValuEngine
ValuEngine downgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a hold rating in a research note published on Wednesday.
Several other equities research analysts also recently issued reports on LIVN. BidaskClub downgraded LivaNova from a strong-buy rating to a buy rating in a report on Tuesday, December 12th. Needham & Company LLC began coverage on LivaNova in a report on Wednesday, August 23rd. They issued a hold rating for the company. Canaccord Genuity restated a hold rating and issued a $71.00 price target on shares of LivaNova in a report on Wednesday, September 20th. BTIG Research restated a hold rating on shares of LivaNova in a report on Tuesday, November 7th. Finally, Jefferies Group increased their price target on LivaNova from $76.00 to $80.00 and gave the stock a buy rating in a report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $79.71.
LivaNova (NASDAQ:LIVN) traded down $1.01 during midday trading on Wednesday, reaching $79.69. The company had a trading volume of 185,300 shares, compared to its average volume of 394,353. The company has a market capitalization of $3,890.67, a P/E ratio of 23.26, a PEG ratio of 2.42 and a beta of 0.61. The company has a quick ratio of 1.42, a current ratio of 2.03 and a debt-to-equity ratio of 0.04. LivaNova has a fifty-two week low of $44.58 and a fifty-two week high of $88.56.
In other news, Director Hugh M. Morrison sold 1,830 shares of the company’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total transaction of $161,040.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $81.39, for a total value of $81,390.00. The disclosure for this sale can be found here. Insiders have sold 6,830 shares of company stock valued at $569,350 over the last ninety days. 0.28% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Shelton Capital Management acquired a new position in LivaNova during the third quarter valued at approximately $209,000. Pura Vida Investments LLC boosted its position in LivaNova by 10.2% during the third quarter. Pura Vida Investments LLC now owns 154,273 shares of the company’s stock valued at $10,808,000 after purchasing an additional 14,271 shares during the last quarter. California Public Employees Retirement System boosted its position in LivaNova by 2.5% during the third quarter. California Public Employees Retirement System now owns 149,307 shares of the company’s stock valued at $10,460,000 after purchasing an additional 3,641 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in LivaNova by 248.7% during the third quarter. Janney Montgomery Scott LLC now owns 12,916 shares of the company’s stock valued at $905,000 after purchasing an additional 9,212 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in LivaNova during the third quarter valued at approximately $611,000. 86.00% of the stock is owned by hedge funds and other institutional investors.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.